<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047175</url>
  </required_header>
  <id_info>
    <org_study_id>147DDI13019</org_study_id>
    <nct_id>NCT02047175</nct_id>
  </id_info>
  <brief_title>CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug-drug interaction of
      CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple-dose, two-arm, one-sequence · crossover study to evaluate
      the safety and pharmacokinetics after oral concurrent administration telmisartan/s-amlodipine
      and rosuvastatin in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt,ss of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R of Telmisartan/S-Amlodipine</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R of Rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>A(Telmisartan/S-Amlodipine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A(Telmisartan/S-Amlodipine)
: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(Rosuvastatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B(Rosuvastatin)
: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/S-Amlodipine</intervention_name>
    <description>Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days</description>
    <arm_group_label>A(Telmisartan/S-Amlodipine)</arm_group_label>
    <other_name>Telminuvo tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20mg 1T PO, QD for 5days</description>
    <arm_group_label>B(Rosuvastatin)</arm_group_label>
    <other_name>Crestor tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/S-Amlodipine + Rosuvastatin</intervention_name>
    <description>Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days</description>
    <arm_group_label>A(Telmisartan/S-Amlodipine)</arm_group_label>
    <other_name>Telminuvo tablet + Crestor tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/S-Amlodipine + Rosuvastatin</intervention_name>
    <description>Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days</description>
    <arm_group_label>B(Rosuvastatin)</arm_group_label>
    <other_name>Telminuvo tablet + Crestor tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is a male or female between 20 and 45 years of age (inclusive) at the
             pre-study (screening)

          2. Participant who has a body weight that is &gt;55kg(male) or &gt;50kg(female) with ideal body
             weight of 80-120% (ideal body weight) = {Height(cm) - 100} * 0.9

          3. If female, must include more than one among the items

               1. The menopause (there is no natural menses for at least 2 years)

               2. Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or
                  other methods of infertility condition)

               3. The male partner infertility before screening (Demonstrated azoospermia after
                  vasectomy)and if this man is the only partner of the female subject.

               4. you are using one of the following contraceptive measure for 3 months before
                  screening, and Necessarily you agree that used continuously contraceptive measure
                  during the clinical trial and for 1 month after the final dosing investigational
                  product.(But, should not use a device of contraception or oral contraceptive drug
                  that containing a hormonal caused telmisartan, s-amlodipine, atorvastatin calcium
                  drug interactions during the clinical trials)

                    -  Abstinence.

                    -  Physical interrupt method (such as a condom, contraceptive diaphoretic or
                       cervical cap)

               5. In case of women of childbearing age, the serum β-hCG pregnancy test is negative
                  before taking the investigational product, and urine β-hCG test is negative
                  before taking the investigational product.

          4. If men has sexual life with women of childbearing age, Necessarily he agrees that use
             condoms during clinical trials and do not sperm donation during clinical trials and
             until one month after the final dosage of investigational products

          5. Those who fully understand about this clinical trial after enough hearing, and then
             decided to join the clinical trials by themselves and to comply with the precautions
             written consent.

        Exclusion Criteria:

          1. The subject has a previous history of any clinically significant cardiovascular,
             pulmonary, renal, endocrine, hematological, gastro-intestinal, neurological,
             psychiatric, or malignancy.

          2. Have a gastrointestinal disease history that can affect drug absorption (Crohn's
             disease, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery).

          3. Hypersensitivity reaction to drug or clinically significant hypersensitivity reaction
             in the history of Investigational drugs (telmisartan, s-amlodipine or rosuvastatin
             calcium) or additives.

          4. An impossible one who participates in clinical trial including screening tests(medical
             history taking, V/S, physical examination, 12-lead ECG, blood &amp; urine laboratory test
             result)

          5. Defined by the following laboratory parameters:

               -  Hemoglobin &lt; 13.0 g/dL(male), Hemoglobin &lt; 12.0 g/dL(female)

               -  AST, ALT&gt; 1.25* upper limit of normal range

               -  Total bilirubin &gt; 1.5* upper limit of normal range

               -  CPK &gt; 1.5* upper limit of normal range

               -  eGFR(using by MDRD method) &lt; 60 mL/min/1.73m2

          6. Sitting SBP &gt; 150 mmHg or &lt; 90 mmHg, Sitting DBP&gt; 100 mmHg or &lt; 50 mmHg , after
             5minuts break.

          7. Drug abuse or have a history of drug abuse showed a positive for urine drug test.

          8. Female Participant is pregnant or lactating

          9. A heavy caffeine consumer(caffeine&gt;5cups/day), alcohol consumer(alcohol&gt;210g/week), or
             smoker(cigarette&gt;10cigarettes/day)

         10. Participation in any other study and have received any other investigational drug or
             device within 90 days prior to study treatment.

         11. Administration of drug metabolizing enzyme inducers or inhibitors such as barbitals
             within 30 days prior to the first dosing.

         12. Blood donation (1 unit or more) within 60 days prior to study treatment or plasma
             donation within 30 days prior to study treatment.

         13. Taking foods containing grapefruit within 7 days before the beginning of study
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days
             before the beginning of study treatment)

         14. Subject takes ethical drug or herbal medicine within 14days, OTC or vitamins within
             7days before the beginning of study treatment.

         15. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-seok Yim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The catholic university of Korea, seoul ST.Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

